“Ozempic feet” is a colloquial term describing reports of foot pain or changes in foot appearance among patients using GLP-1 receptor agonists like semaglutide. While not a recognized medical diagnosis, clinicians attribute these symptoms to rapid weight loss, which can reduce the protective fat pads on the soles of the feet, leading to increased pressure, discomfort, and altered gait.
The Connection Between Rapid Weight Loss and Foot Pain
Patients using medications such as Ozempic or Wegovy often experience significant and rapid reductions in body mass. According to the Mayo Clinic, while these drugs are effective for weight management, the body undergoes various structural changes during substantial weight loss. The feet contain specialized fat pads designed to cushion the bones during walking and standing. When weight loss occurs quickly, the body may lose fat from these areas, effectively reducing the natural shock absorption of the foot.
This loss of adipose tissue can lead to conditions like metatarsalgia—pain and inflammation in the ball of the foot. As the protective padding thins, patients may feel as though they are walking directly on their bones, particularly when wearing unsupportive footwear or standing for long periods.
Recognizing Symptoms and Clinical Observations
Though “Ozempic feet” is not a formal clinical term, podiatrists have observed an increase in patients seeking treatment for foot-related discomfort coinciding with the surge in GLP-1 medication use. Common complaints include:
* Increased sensitivity or pain in the heels and balls of the feet.
* Changes in how shoes fit, potentially due to the loss of soft tissue volume.
* Increased fatigue when standing or walking, attributed to the lack of natural cushioning.
Medical professionals, including those at the American Orthopaedic Foot & Ankle Society, emphasize that foot pain is a common side effect of rapid weight loss regardless of the method used to achieve it. Whether through bariatric surgery, diet, or pharmacological intervention, the loss of subcutaneous fat is a systemic process that affects the feet just as it affects other parts of the body.
Managing Discomfort During Treatment
For those experiencing foot pain while on GLP-1 therapy, conservative management is typically the first line of defense. The American College of Foot and Ankle Surgeons suggests that patients can often mitigate these symptoms by:
* Upgrading Footwear: Switching to shoes with better arch support and extra cushioning can compensate for the lost fat pads.
* Using Orthotics: Over-the-counter or custom-molded inserts can redistribute pressure away from sensitive areas of the foot.
* Monitoring Activity: Gradually increasing physical activity levels allows the body—and the feet—to adapt to structural changes.
* Consulting a Specialist: If pain persists or interferes with daily life, a podiatrist can evaluate whether the discomfort is related to fat pad atrophy or an underlying mechanical issue.
Key Takeaways for Patients
* Not a Drug-Specific Side Effect: The phenomenon is linked to the speed of weight loss rather than a direct chemical effect of semaglutide on foot tissue.
* Structural Change: The primary cause is the depletion of the fat pads that provide natural cushioning.
* Consult Your Physician: Always report new or worsening pain to your prescribing doctor to ensure it is not a sign of another condition, such as neuropathy, which can be associated with diabetes.
Patients should remain in contact with their healthcare providers to monitor their overall health during treatment. As weight loss stabilizes, many patients find that their body adjusts to the changes, though supportive footwear remains a vital component of long-term foot health.
Related reading